← Leaderboards
Tanya Siddiqi
Beckman Research Institute/City Of Hope
$833,273
Attributed
$2,499,820
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $719.6K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,499,820 · 1
By mechanism
R01$2,499,820 · 1
Top collaborators
- Stephen J Forma4 shared
- Xiuli Wang4 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Hua E Yu$13,108,796
- Xiuli Wang$2,702,470
- Hsun Teresa Ku$4,643,245
- Sophia S. Wang$9,836,949
- Robert Wi Chen$1,186,185
Research focus
Non-Hodgkin&AposCorrelative StudyCellsAnimal ModelB-Cell Acute Lymphoblastic LeukemiaAngiopoietinsAutologousBlood - Brain Barrier AnatomyB-LymphocytesBrainCar T Cell TherapyCd19 GeneBiological MarkersCell PhysiologyClinical TrialsBloodCentral Nervous System DiseasesCentral Nervous System LymphomaCerebral VentriclesCerebrospinal FluidCharacteristicsChimeric Antigen Receptor T CellsCitiesCognitive
Grant awards (4)
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma$710,483
R01 · FY2025 · CA
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma$364,612
R01 · FY2024 · CA
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma$705,167
R01 · FY2023 · CA
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma$719,558
R01 · FY2022 · CA